Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: J Thorac Oncol. 2019 Mar 1;14(5):802–815. doi: 10.1016/j.jtho.2018.12.038

FIGURE 1. Clinical information for patients with resistance to EGFR TKI and BRAF fusions.

FIGURE 1.

A. Disease course of patient 2, found to have acquired resistance to osimertinib and AGK/BRAF fusion. B. Disease course of patient 4, found to have acquired resistance to erlotinib and progressive mediastinal disease with AGK/BRAF fusion.